Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ajinomoto Obtains Ulcerative Colitis Drug From German Dr. Falk Pharma

This article was originally published in PharmAsia News

Executive Summary

Ajinomoto obtains Japanese marketing rights for ulcerative colitis drug Salofalk (mesalamine) from German drug maker Dr. Falk Pharma GmbH. The payment is estimated to be around ¥10 billion ($99.8 million). Currently available in Europe, Salofalk treats colitis ulcerative colitis with once-daily dosing. Ajinomoto plans to test and find the most effective dose for Japanese patients and to commercialize the drug in three to five years. Ajinomoto plans to expand its pharmaceutical business by 20 percent in the next five years, which would mean it would be second only to its food business. Ulcerative colitis has no known cause and has been designated as an intractable disease by Japan's Ministry of Health, Labor and Welfare. (Click here for more - Japanese language
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC068143

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel